4,916 Shares in AbbVie Inc. $ABBV Purchased by Bernicke Wealth Management Ltd.

Bernicke Wealth Management Ltd. purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,916 shares of the company’s stock, valued at approximately $1,286,000.

Several other hedge funds have also bought and sold shares of ABBV. Ranch Capital Advisors Inc. increased its holdings in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after buying an additional 4,017 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in shares of AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after acquiring an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of AbbVie during the 2nd quarter worth about $23,557,000. State Street Corp boosted its stake in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Finally, Wedge Capital Management L L P NC boosted its stake in shares of AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after acquiring an additional 9,380 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.2%

Shares of ABBV opened at $295.18 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93. The stock has a market cap of $521.76 billion, a PE ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. The firm’s fifty day moving average is $275.51 and its two-hundred day moving average is $240.91.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.86 earnings per share. As a group, research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is currently 125.30%.

Key AbbVie News

Here’s some of the latest news about ABBV:

• Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ABBV shares. Bank of America restated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Argus increased their price target on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. The Goldman Sachs Group raised their price objective on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Finally, Barclays raised their price objective on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $297.46.

Insider Transactions at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.